A neobladder reconstruction technique that is performed using robotic assistance appears to be a safe, less invasive option in patients with aggressive bladder cancer.
2024 Medicare final rule: Here comes code G2211
"The conversion factor is slated to undergo a reduction of approximately 3.37% for 2024, decreasing from $33.89 in 2023 to $32.74," write Jonathan Rubenstein, MD, and Mark Painter.
How APPs can bridge the gap in urologist shortages
In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.
Study links PARP inhibitors to increased risk of hematologic toxicity in mCRPC patients
A recently published study found an association between PARP inhibitor treatment and an increased risk of hematological adverse events, including anemia, thrombocytopenia, and neutropenia, in patients with metastatic castration-resistant prostate cancer.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Ambient clinical documentation shows promise for physicians
Technology may save health care professionals’ time and help reduce burnout.
Can remote patient monitoring help combat the staffing shortage?
"As more patients become interested in remote patient monitoring and case studies continue to show improved patient outcomes, practices must seek ways to integrate these tools into their workflows," writes Lucienne Marie Ide, MD, PhD.
2 Clarke Drive Cranbury, NJ 08512